Clever Culture Systems (CC5) Q4 2026 earnings summary

Executive summary

• Doubled large global pharmaceutical customers to eight in FY26, expanding the APAS® Independence installed base and underpinning future sales growth.

• Hosted APAS® Discovery Day at AstraZeneca, strengthening industry relationships and showcasing technology to customers from 10 countries.

• Entered FY27 with a robust pipeline: 100 instrument sales potential from existing pharma customers and 80 from new qualified prospects.

Financial highlights

• Cash balance at 30 June 2026 was $1.7 million, with $3.4 million in known/committed inflows expected over the next two quarters.

• Net cash outflows for the quarter were $0.3 million, with $1.7 million outflows from operating/investing and $1.4 million inflows from financing.

• Annual recurring revenue from software licenses exceeded $1.3 million.

• Receipts from customers for the quarter were $551,000; year-to-date $4.9 million.

Outlook and guidance

• FY27 sales growth expected, driven by both existing and new qualified pharmaceutical customers.

• Expansion phase to leverage established customer base for multiple instrument sales and increased recurring revenue.

• Validation services capability developed to accelerate customer adoption and shorten sales cycles.